TransAlta: Q2 Earnings Insights

  TransAlta (NYSE:TAC) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings TransAlta reporting an EPS of $-0.24.

 

TransAlta (NYSE:TAC) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM.

Here’s what investors need to know about the announcement.

Earnings

TransAlta reporting an EPS of $-0.24.

Revenue was down $144.84 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.48 which was followed by a 2.71% increase in the share price the next day.

Here’s a look at TransAlta’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 0.06 0.06 0.10  
EPS Actual 0.54 -0.23 0.35 -0.03
Revenue Estimate 424.88M 460.49M 427.75M 489.36M
Revenue Actual 580.09M 483.85M 675.07M 503.74M

To track all earnings releases for TransAlta visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Celldex Therapeutics Presented Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023; Said Rapid, Profound And Durable Responses Across Multiple Dosing Groups With Favorable Safety Profile Observed

Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today updated data from the Company's Phase 1b clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines.

CLDX